BioAscent recently published an article in Drug Discovery World, a quarterly business review of drug discovery and development, voicing opinions of some of the industry’s leading experts. The piece was featured in the Autumn 2019 edition.
The article, written by Dr Philip Jones, Chief Scientific Officer at BioAscent and Dr Stuart McElroy, Director of Biosciences, is titled ‘Reducing the PAINS in high throughput screening: assay design as a tool for maximising efficiency’.
It explores, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource.
Reproduced with kind permission of Drug Discovery World (www.ddw-online.com).